An arthritis drug, upadacitinib, shows promising results for people with severe alopecia areata, according to results from large Phase 3 clinical trials. The studies report that some participants regain substantial scalp hair over about 24 weeks.
Both outlets describe upadacitinib as acting by targeting the immune response involved in the condition, which affects hair follicles. NDTV says the trials find that up to 55% of patients regain at least 80% of scalp hair within 24 weeks. Times of India similarly reports significant regrowth within the same timeframe, highlighting potential benefits for patients’ quality of life.
While the outcomes are presented as encouraging, both sources indicate the need for further evidence. Times of India specifically notes that more research is required to confirm long-term safety and effectiveness. The overall framing differs mainly in emphasis—NDTV focuses on specific regrowth benchmarks, while Times of India also points to patient-reported improvements—but both agree on the trial timeframe and the drug’s mechanism.
